Immunogenicity in mice of varicella-zoster virus glycoprotein I expressed by a vaccinia virus-varicella-zoster virus recombinant
Several vaccinia virus (VV)-varicella-zoster virus (VZV) recombinants expressing glycoprotein I (gpI) of VZV were isolated from the Prague strain of VV. One of these, v46, was inoculated intraperitoneally into mice. Groups of mice were bled 4 and 8 weeks later and their sera were examined for anti-VZV and anti-VV antibodies by ELISA. At 4 weeks, all mice inoculated with the three largest virus doses (107 , 106 and l0 s p.f.u.), and at 8 weeks all mice inoculated with the four highest virus doses (107, 106, 105 and 104 p.f.u.), had developed both anti-VV and anti-VZV antibodies. Antibodies were also detected in a high proportion of mice infected with lower doses of virus and in some instances VZV antibodies were present in the absence of VV antibodies. None of the animals inoculated in parallel with either a thymidine kinase-negative mutant of the original VV or diluent alone developed antibody reactive with VZV. The specificity of the reaction was assessed further by Western blotting using anti-gpI monoclonal antibodies as a positive control. Sera from animals immunized with v46 possessed antibody capable of neutralizing extracellular VZV in the presence of complement.
Varicella-zoster virus (VZV) causes infection only in humans. It induces two diseases, varicella, which is the clinical manifestation of primary infection with the virus and occurs predominantly in children, and herpes zoster which occurs predominantly in adults as a consequence of reactivation of latent VZV infection.
In the past few years there has been remarkable progress in the understanding of the molecular biology of VZV. The whole genome has been sequenced (Davison & Scott, 1986 ) and shown to contain five glycoprotein (gp) open reading frames (ORFs). A considerable amount of data has been produced on the immunology of the VZV gps (Arvin et al., 1986; Soike et al., 1987; Brunell et al., 1987; Grose & Litwin, 1988; Diaz et al., 1988; . Of these, gpI, with an Mr of 90K to 98K, is the most abundant and immunogenic, and is the predominant gp in VZV-infected human cell membranes (Keller et al., 1984; Montalvo & Grose, 1986; Dubey et al., 1988) . Anti-gpI antibody has been detected in subjects with recent natural primary and recurrent infections, in subjects vaccinated with live VZV vaccine and also in subjects known to have been infected with VZV in the past (Dubey et al., 1988) . Monoclonal antibody (MAb) to VZV gpI mediates antibody-dependent cellular cytotoxicity and, in the presence of exogenous complement, also neutralizes infectious virus in vitro (Grose & Litvin, 1988; Grose, 1989) . The gene for gpI is located in the Us region of the VZV genom e (Davison, 1983; Vafai et al., 1986) . Recently, Cabirac et al. (1988) have reported a vaccinia virus (VV)-VZV recombinant expressing VZV gpI during replication in tissue culture.
This study had two goals. First, we wanted to construct VV-VZV recombinants using the Prague strain of VV (Slonim & Hulenov~, 1969) instead of wild-type WR VV . Prague virus, used for vaccination in Czechoslovakia since 1892, exhibits very low reactivity and high immunogenicity in vaccinees (Slonim & Kratochvilovfi, 1978) and is therefore considered convenient for the derivation of recombinant vaccines. Second, we wanted to obtain data on the immunogenicity of the VV-VZV recombinant in laboratory animals. This information will be needed if a recombinant VZV vaccine for human use is considered in the future.
As the starting material, we used VZV HindIII DNA fragments cloned into pBR322; these materials were produced and kindly provided by Dr R. Hyman, Department of Microbiology and Immunology, Pennsylvania State University, Hershey, Penn., U.S.A. (Ecker & Hyman, 1982) . The HindIII C fragment contains the VZV Us region (5232 bp) flanked on each side by approximately 7320 bp of internal repeat and terminal repeat sequences (Ecker & Hyman, 1982) gpI. The VZV HindlII C fragment cloned into pBR322 was cleaved with PvulI, KpnI and BglI. From the resulting fragments, that containing the gpI gene was selected and isolated using the method of Cabirac et al. (1988) . The 2469 bp BglI fragment was blunt-ended with T4 DNA polymerase and inserted into the SmaI site of the VV transfer vector pGS20, provided by Dr B. Moss, NIH, Bethesda, Md., U.S.A. The construction of the vector is shown in Fig. 1 . For recombination, isolation of recombinants and their characterization, and growth of other viruses, we used thymidine kinase-negative (TK-) Rat-2 cells, human diploid LEP cells and monkey CV-1 cells. The origin of these cells and their cultivation and maintenance were as described (KutinovA et al., 1990) ; VV-VZV recombinants were prepared by a standard procedure (KutinovA et al., 1990) . In brief, CV-I cells were infected with the Prague strain of VV at an m.o.i, of 0-1 p.f.u./cell and, after a 2 h incubation at 37 °C, the cultures were transfected with calcium phosphateprecipitated pGS20-VZVgpI plasmid DNA; virus was harvested 48 h after infection. TK-viruses were selected in Rat-2 cells in the presence of 100 ~tg 5-bromo-2'-deoxyuridine/ml and plaque-purified in the same system. VV-VZV recombinants were distinguished from spontaneous TK-mutants by dot blot hybridization using 3zp_ labelled, cloned VZV DNA (BglI fragment of HindIII fragment C) as the probe. A total of 18 viruses which hybridized with labelled VZV DNA were selected. Extracts from Rat-2 cell cultures infected with these viruses were investigated by ELISA and Western blotting (WB). Antigens for ELISA were prepared from Rat-2 cell cultures infected with VV-VZV recombinants. When c.p.e, reached 70 to 90~, the cells were scraped from the glass into Hanks' balanced salt solution (HBS), washed, resuspended in HBS (2 ml per 1200 ml bottle culture) and sonicated in an ice bath for 4 rain at 23 kHz. After clarification by centrifugation at 1000g for 20 min, aliquots of the supernatant were stored at -70 °C. Identically processed extracts from Rat-2 cells either infected with a TK-mutant of VV strain Prague or mock-infected, and from LEP cells either infected with VZV strain M (isolated and provided by Dr J. TrlifajovA, Institute of Hygiene and Epidemiology, Prague, Czechoslovakia) or mock-infected, served as control antigens. Human convalescent serum from a patient with herpes zoster, which did not contain VV antibodies, was used for detecting gpI; human serum free of both VV and VZV antibodies served as a control. For the ELISA, microtitre plates (Novogen) were coated with 200 ~tl of appropriate antigen dilution (al~proximately 1 ~g prorein/well) in 50 mM-bicarbonatecarbonate buffer pH 9-6 overnight at room temperature. Unbound material was removed and free binding sites were blocked with 1 ~o bovine serum albumin in the same buffer for 1 h at room temperature. The weUs were washed repeatedly with washing buffer (8 mM-phosphate buffer pH 7-2, 350 mM-sodium chloride, 1 ~ Triton X-100). Either positive or negative human serum (0.1 ml) diluted 1:600 in washing buffer supplemented with 10 ~o bovine serum was then added and the mixture was incubated in duplicate wells for 1 h at room temperature. After repeated rinsing with washing buffer, peroxidaseconjugated swine anti-human immunoglobulin (SwAHu; Sevac) was added for 1 h at room temperature, the wells were washed and o-phenylenediamine (in 35 mM-citrate buffer pH 5.0) was added. The colour reaction was stopped by adding 2 M-H2SO, ~ and the A490 was determined using a Titertek Multiskan MCC 340 (Flow Laboratories). All recombinant antigens giving an A reading in an ELISA with the positive serum twofold greater than that with the control antigen were considered positive. From the 18 preparations tested four, vl, v2, v36 and v46, gave a positive reaction, indicating that they contained amounts of VZV antigen detectable by the technique used. These materials were further tested by WB using the method of Dubey et al. (1988) . Antigens prepared by this method were electrophoresed in discontinuous 8 ~ SDSpolyacrylamide gels under reducing conditions (1 ~ 2-mercaptoethanol). Separated proteins were electroblotted onto a nitrocellulose membrane and incubated with the VZV antibody-positive (but VV antibody-negative) serum, and VZV and VV antibody-negative serum diluted 1:50 in PBS, 4~o non-fat dry milk. The membrane was incubated with SwAHu and reacted with 4-chloro-l-naphthol (Koch Light Laboratories). The results are shown in Fig. 2 . It can be seen that all four viruses that gave a positive reaction in the ELISA were also positive by WB.
As already mentioned, our efforts were aimed mainly at determining the immunogenicity of the VV-VZV recombinants in laboratory animals and for this purpose we selected recombinant v46. This virus and one of the T K -mutants of VV strain Prague isolated in previous experiments (unpublished results) were propagated on the chorioallantoic membranes of l 1-day-old chick embryos. Virus was concentrated, purified (Joktik, 1962) and tested for the presence of VZV gpI; these tests yielded negative results. Both viruses were diluted in tissue culture medium supplemented with 5 ~ peptone and inoculated intraperitoneally into mice in doses ranging from 101 to 107 p . f . u . ; 10 4-week-old white outbred mice of the D66in strain were inoculated with each virus dose. An additional group of mice was inoculated with the dilution medium only. The mice were caged in groups according to the virus dose administered. Five mice from each group were bled 4 and 8 weeks later and their sera were stored at -2 0 °C until investigation by ELISA. The VZV antigen for the ELISA was prepared in LEP cells, whereas the VV antigen was prepared in CV-1 cells, and control antigens were prepared in corresponding mock-infected cultures. One gg of each antigen per well was used (as determined later in box titration with VZV antibody-positive murine sera, this amount of VZV antigen contained 3 to 4 gpI antigen units). Individual murine sera were diluted 1:40 for the VZV antibody assay and 1:10 for the VV antibody assay. The test was performed as described above using peroxidase-conjugated swine anti-mouse immunoglobulin (SWAM, Sevac). Serum was considered VZV antibody-positive when the A exceeded 0-3. This cut-off value was established by testing sera from 40 mice not exposed to VZV antigen and was just greater than the mean A + 3 S.D. In the case of VV the cut-off point, determined similarly, was 0.2. The results of anti-VZV and anti-VV antibody determinations are summarized in Fig. 3 (a and b) . All mice infected with the three highest virus doses had developed antibodies to both viruses 4 weeks after infection (Fig. 3a) . The sera of some mice infected with lower doses were free of antibody; more of these lacked anti-VV than anti-VZV antibodies. Gener-ally, the reactivity of sera with the VZV antigen was greater than that with the VV antigen and this was most marked in mice inoculated with the smallest virus doses. None of the mock-infected mice developed antibody to either antigen. At 8 weeks (Fig. 3b) , all mice infected with the four highest virus doses possessed antibodies to both viruses and the reactivity was generally higher in these animals than in those bled earlier. It is noteworthy that the difference between the reactivities with VZV and VV somewhat diminished between weeks 4 and 8 suggesting that the development of the anti-VV antibody monitored in the assay system used was slower than the development of anti-VZV gpI antibody. Again, none of three sera from mock-infected mice possessed either antibody. Sera from mice infected with a VV T Kmutant were tested for VV and VZV reactivity in parallel. The reactivity of these sera with VV was directly proportional to the dose of virus administered and was somewhat lower than that of sera from animals inoculated with recombinant v46 (not shown); none of these sera was reactive with VZV antigen.
To prove that the development of the anti-gpI antibody was conditioned by v46 replication and not by preformed gpI present in the virus inoculum, we also tested sera from mice inoculated with u.v.-inactivated v46. Virus was diluted 1 : 10 in PBS and irradiated using a germicidal u.v. lamp for between 2 and 20 min. After 15 min irradiation the survival rate was reduced to less than 10 -7, as revealed by titration in CV-1 cells This preparation was diluted 10 -3 and 10 -5 and inoculated into groups of five mice. These doses corresponded to 103 and 105 p.f.u., respectively, of the original virus. Parallel groups of mice were inoculated with the same doses of non-irradiated v46. Mice were bled 4 weeks later and their sera were examined for the presence of anti-VV and anti-VZV antibodies. All mice inoculated with 105 p.f.u. of non-irradiated virus developed both anti-VV and anti-VZV antibodies. After administration of a lower dose of this virus, all mice possessed anti-VZV antibody whereas some were free of VV antibody. All sera from mice inoculated with u.v.-irradiated virus were free of both anti-VV and anti-VZV antibodies (data not shown).
To characterize further the specificity of the anti-VZV reaction we attempted to demonstrate the presence of anti-VZV gpI antibody in murine sera by WB. The procedure described above was used with pools of murine sera (diluted 1 : 50), which had been identified as either positive or negative for VZV antibody by ELISA. For identification of gpI, two anti-gpI MAbs (diluted 1 : 50), 90.1 and 79.1, kindly provided by Dr A. Vafai, Department of Neurology, University of Colorado School of Medicine, Denver, Co., U.S.A., were employed . The results are shown in Fig.  4 . Serum from non-immune mice did not show any reactivity, whereas antibody reactive with VZV in ELISA manifested itself as a broad band with a peak of intensity at 90K. The location of the band was the same using both anti-gpI MAbs. The complement-dependent neutralizing capacity of murine sera containing anti-gpI antibodies was examined in a plaque reduction assay. Cell-free VZV was prepared as described by Ilobi & Martin (1989) . In brief, VZV-infected LEP cells exhibiting extensive cytopathic changes were added to uninfected LEP cells at a ratio of 1:10. After 26 h cultivation, cells were scraped into Eagle's MEM supplemented with 5~ sucrose, 0.1~ sodium glutamate and 10~ foetal calf serum, sonicated and centrifuged down. The supernatant was stored at -7 0 °C. Equal amounts of virus (diluted 1:2), heatinactivated (56 °C, 30 min) serum (undiluted or diluted 1:3) and fresh guinea-pig serum (diluted 1:3) were incubated for 1 h at 37 °C, and two Petri dish LEP cell cultures were inoculated with 0-3 ml of each mixture. Plaques were counted after a 7 day incubation in a humidified CO, incubator. Four serum pools from mice immunized with 106 and 107 p.f.u, of v46 in two different experiments were investigated. Serum from a child who had recently suffered from varicella and pooled sera from unimmunized mice, mice immunized with virus diluent alone and mice immunized with 106 and 107 p.f.u, of a TK-mutant of the original VV served as controls and were tested in parallel (Table 1) . It can be seen that all serum pools from mice immunized with v46 reduced the plaque count significantly. Comparable results were obtained in three repeated tests. It should be added that, in agreement with a previous report on anti-gpI antibody (Grose, 1989) , no neutralization of VZV was observed in the absence of complement. The present data indicate that the VV-VZV recombinant v46, which was derived from VV strain Prague, produces VZV gpI both in vitro and in vivo; gpI produced in vivo was apparently highly immunogenic for mice. Athough the antibody response was clearly influenced by the size of virus dose, even doses as low as 10 p.f.u, were capable of inducing detectable amounts of anti-gpI antibody in most animals (six of 10). This remarkable result may be due either to the large amount of gpI produced in vivo and/or its presence in a form ensuring its highly efficient presentation to the immune system. An alternative possibility is that the mice used had been infected previously with a mouse herpesvirus sharing some important epitopes with VZV gpI and that the antibody response was in fact a booster effect. The absence of this type of antibody in mice not inoculated with v46 (about 70 animals tested) does not favour this possibility. Experiments to clarify this point are under way.
